Company / FCF Margin
Aclaris Therapeutics, Inc. FCF Margin History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-603.4%
FY2025
5-year range
-775.6% / -229.1%
FY2021-FY2025
Trend
-136.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FCF Margin has fluctuated over the past 9 years, ranging from -3321.3% in FY2019 to -229.1% in FY2022.
Based on SEC 10-K filings.
-603.4% in FY2025 with a 5-year CAGR of +1057.6%.
Improved from -775.6% to -603.4% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- -374.3pp
- 5-Year Change
- +1057.6pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, fcf margin decreased 136.8% year-over-year.
- Peak fcf margin was recorded in FY2022.
- Lowest fcf margin in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -603.4% | -136.8% |
| FY2024 | -254.8% | +67.1% |
| FY2023 | -775.6% | -238.5% |
| FY2022 | -229.1% | +70.5% |
| FY2021 | -775.6% | +53.3% |
| FY2020 | -1661.0% | +50.0% |
| FY2019 | -3321.3% | -100.0% |
| FY2018 | -1661.0% | -33.9% |
| FY2017 | -1240.4% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026